Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. GlaxoSmithKline (GSK) upgraded to Buy from Hold at Berenberg with analyst Alistair Campbell saying Glaxo's long-term value is emerging and the market underappreciates the strength and breadth of its diversified business. 2. Rayonier Advanced Materials (RYAM) was upgraded to Buy from Hold at Vertical Research and to Buy from Neutral at BofA/Merrill. 3. Red Robin (RRGB) upgraded to Buy from Hold at Canaccord with analyst Lynne Collier citing greater confidence in its top-line drivers and in stable to improving casual dining trends. Collier raised her price target to $90 from $72 on Red Robin shares. 4. Star Bulk Carriers (SBLK) upgraded to Buy on valuation at Seaport Global with analyst Magnus Fyhr citing the pullback in shares and favorable drybulk market fundamentals. Fyhr raised his price target on Star Bulk shares to $13 from $11.50. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

GSK announced positive results from the pivotal EAGLE-1 phase III trial for gepotidacin, a potential first-in-class oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhoea in adolescents and adults. These results will be presented on 30 April 2024 at the European Society of Clinical Microbiology and Infectious Diseases, ESCMID, Global in Barcelona, Spain. The results from EAGLE-1 are based on a primary endpoint of microbiological response at the Test-of-Cure visit 3-7 days after treatment. The trial showed that gepotidacin was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular ceftriaxone plus oral azithromycin combined therapy, a leading combination treatment regimen for gonorrhoea. The safety and tolerability profile of gepotidacin in the EAGLE-1 trial was consistent with results seen in phase I and II trials. The most commonly reported adverse events in gepotidacin subjects were gastrointestinal. All AEs were mild or moderate except for one severe, unrelated event in each treatment arm and one unrelated serious event in the gepotidacin arm.